



Villers-lès-Nancy, 7th November 2011 – 18h30 (CET)

**PRESS RELEASE**

**Strong growth in Turnover for the 3rd quarter 2011: + 9.7 %**

M€	2011	2010	Variation
1st half year 2011	50.23	46.44	+ 8.2 %
<b>3rd quarter 2011</b>	<b>22.40</b>	<b>20.43</b>	<b>+ 9.7 %</b>
Turnover at end of September (non audited)	72.64	66.88	+ 8.6 %

During the first nine months of the year, the PHARMAGEST Group produced turnover of 72.64 M€, an increase of 8.6 % compared to the previous year.

Turnover for the 3rd quarter alone reaches 22.40 M€, a rise of 9.7 % compared to the 3<sup>rd</sup> quarter 2010.

**Update on activity:**

- **Pharmacy France** business recorded 4.7% growth over 9 months (compared to the same period in 2010) with turnover of 59.7 M€:
  - Configuration sales + 5.6 % at 30th September 2011 compared to 30th September 2010
  - Recurring income (maintenance and data bases): + 4.2 %
  - Sales of products developed by Pharmagest Interactive: + 1.8 %

During the 3<sup>rd</sup> quarter 2011 alone, the historic increase in business from the Pharmagest Group stands at 7.5 %, brought about by a dynamic rise in sales and an attractive post-holiday offer.

- **Pharmacy business in Belgium and Luxembourg** maintains a level of growth of 5.7 % over the first nine months of the year 2011. Despite a particularly sluggish summer period in Belgium and the carrying over of a certain number of transactions, the order book for the end of the year means we can look forward to a clear improvement in the situation.
- **Laboratory business**, with turnover of 8.64 M€, a rise of 40.2 % at 30th September 2011 compared to 30th September 2010, represents the second business in terms of contribution to the Group's turnover.
- **Care home business** is continuing with its strong increase: Its turnover stands at 2.04 M€ and is up by 31.6 % during the first 9 months of the year 2011 compared to 2010.

**Perspectives:**

**In keeping** with the company's expectations, the Pharmagest Group's business over the rest of the year should maintain its rhythm and confirms the relevance and solid aspect of its economic model.

The process that has been got underway during these last months means the Pharmagest Group can be optimistic about the future: Intecum and Diatelic provide 2 new forms of technological expertise, 1 in every 3 pharmacies is equipped with the LGPI Global Services<sup>®</sup>,

the acquisition of holdings in Domedic Group Inc. that enables the Pharmagest Group to offer in Europe, through its subsidiary Domedic Europe, the DO-Pill Secure™, the first intelligent pill dispenser to help with observance of medical treatments. In accordance with its announcement last October, Pharmagest Interactive has successfully integrated the DO-Pill Secure™ into the LGPI Global Services®.

Reassured by these elements, Pharmagest Interactive maintains a calm outlook regarding medium term growth prospects.

**Reminder:**

**Pharmagest Interactive will hold a press conference tomorrow, Tuesday 8th November 2011 at 10h30 (Salons du Louvre) in order to comment on the acquisition of holdings in Domedic Group Inc., and to announce the launch of its intelligent pill dispenser, DO-Pill Secure™ in France.**

**Financial calendar:**

- Publication of Q4 turnover figures 10th February 2012

**The Pharmagest Group:**

The PHARMAGEST Group is the French leader in pharmacy information technology, with 43.5% of market share, 9,800 clients and more than 700 staff. Since September 2007, the PHARMAGEST Group has also been enjoying a presence in Northern Europe with 12% market share in Belgium and Luxembourg.

The favoured partner of pharmacists for more than 25 years, the PHARMAGEST Group creates innovative information technology solutions for pharmacies, and develops E-Business E-Media activity with great potential for laboratories.

The PHARMAGEST Group is also developing new software solutions for care homes and day centres for the elderly.

The first Integrated Portal Management Software (LGPI Global Services®), creating entries for the patient, the pharmacist and the laboratory, boosts sales, optimizes purchases and enhances patient advice. It is also the first permanent impact medium for pharmacies, supplying laboratories with direct communication towards the pharmacist and his patients.

Listed on NYSE Euronext Paris™ - Compartment C on the CAC SMALL90 and SBF 250 indices by inclusion

ISIN: FR 0000077687 – Reuters: PHA.PA – Bloomberg: - PMGI FP

***Find out the latest news from the PHARMAGEST Group at [www.pharmagest.com](http://www.pharmagest.com)***

---



**Chairman of the Board of Directors:**

Thierry CHAPUSOT

**Managing Director:**

Dominique PAUTRAT

Tel. 03 83 15 90 67 – [dominique.pautrat@pharmagest.com](mailto:dominique.pautrat@pharmagest.com)

**Analyst and Investor Relations:** Jean-Yves SAMSON

Tel. 03 83 15 90 67 – [jean-yves.samson@pharmagest.com](mailto:jean-yves.samson@pharmagest.com)

**Press Relations:**

FIN'EXTENSO Isabelle APRILE

Tel. 01 39 97 61 22 - [i.aprile@finextenso.fr](mailto:i.aprile@finextenso.fr)